Compare MATX & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | MMED |
|---|---|---|
| Founded | 1882 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.5B |
| IPO Year | 1994 | 2025 |
| Metric | MATX | MMED |
|---|---|---|
| Price | $214.45 | $20.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $163.33 | $22.56 |
| AVG Volume (30 Days) | 304.5K | ★ 1.1M |
| Earning Date | 05-04-2026 | 06-03-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.10 | N/A |
| Revenue | ★ $3,344,500,000.00 | $3,102,000,000.00 |
| Revenue This Year | $4.65 | $15.99 |
| Revenue Next Year | $4.31 | $10.00 |
| P/E Ratio | $33.51 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $86.97 | $10.65 |
| 52 Week High | $230.74 | $19.95 |
| Indicator | MATX | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 75.51 |
| Support Level | $190.90 | $10.68 |
| Resistance Level | $229.37 | N/A |
| Average True Range (ATR) | 7.01 | 0.80 |
| MACD | -0.35 | 0.15 |
| Stochastic Oscillator | 55.39 | 99.31 |
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.